We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Receives Pre-clinical Milestone Payment
News

Evotec Receives Pre-clinical Milestone Payment

Evotec Receives Pre-clinical Milestone Payment
News

Evotec Receives Pre-clinical Milestone Payment

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Receives Pre-clinical Milestone Payment"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The milestone was achieved for the identification and selection of a compound to be advanced into pre-clinical development within an oncology programme and represents the fourteenth milestone achieved in this multi-year, multi-target collaboration.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: “This important milestone achieved as part of our alliance with Boehringer Ingelheim is the fourth against an oncology target and importantly the first oncology programme to enter pre-clinical development for this collaboration.  We continue to enjoy a fruitful scientific relationship with our colleagues at Boehringer in our efforts to drive new drug candidates to the clinic”.

Advertisement